Harvest One Continues to Expand its Licensed LivRelief InfusedTM Product Line with the Listing of Extra Strength Transdermal CBD Cream at the OCS

Vancouver, British Columbia–(Newsfile Corp. – February 3, 2022) – Harvest One Cannabis Inc. (TSXV: HVT) (OTCQX: HRVOF) (“Harvest One” or the “Company“), announced today the launch of its new LivRelief Infused^TM product SKU, Extra Strength Transdermal CBD Cream. This new SKU will be available at the Ontario Cannabis Store (“OCS“) as part of the Company’s brand expansion within the topicals market distribution channels.

Gord Davey, President & Chief Executive Officer of Harvest One, said, “Harvest One’s LivRelief Infused^TM Transdermal CBD Cream continues its momentum as the top selling SKU in the infused topicals category in Ontario for the 12-month period ended January 2022, as ranked by dollars sold, based on OCS Sales Data. The Company is excited to announce the expanded distribution of LivRelief Infused^TM Extra Strength Transdermal CBD Cream, which has been approved for listing at the OCS and will launch this spring at stores across the province. Ontario is the province with the largest cannabis consumption in Canada, having over 1,400^[1] retail stores and serving a population of over 14.8M people. This is another key milestone for Harvest One as we continue to grow and add to our portfolio of infused licensed products.”

Pipeline development, product innovation and the expansion of distribution channels are key strategic initiatives for Harvest One and its brands LivRelief ^TM and Dream Water ^TM. The Company remains committed to innovation and robust product development to ensure it continually meets the needs of the cannabis consumer base. Additionally, the Company intends to further develop its licensed cannabis-infused topicals to bolster its leadership position in the market by expanding its offerings in Canada and other jurisdictions in key global markets as cannabis consumption becomes legal.

LivRelief Infused^TM Extra Strength Transdermal CBD Cream contains 750mgs of CBD and will offer consumers three times the amount of cannabinoids found in the LivRelief Infused^TM Transdermal CBD Cream. With Harvest One’s infused topical portfolio of LivRelief Infused^TM Transdermal CBD Cream, LivRelief Infused^TM Transdermal 1:1 Cream formulation, and now LivRelief Infused^TM Extra Strength Transdermal CBD Cream in the Company’s portfolio, consumers are provided with more choice to better suit their individual needs.

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/2413/112539_harvest%20one%20image.jpg.

For a more detailed description of each of our consumer brands, we encourage you to visit the portfolio pages our website; https://www.harvestone.com/portfolio/infused-topicals/.

About Harvest One

Harvest One is a global cannabis-infused and non-infused CPG leader that develops and distributes premium health, wellness and self-care products with a market focus on solutions for sleeplessness and pain, resulting in the reduction of fatigue and anxiety. Harvest One is a uniquely positioned company in the cannabis space which is commercializing both cannabis-infused and non-infused products. Harvest One has established an impressive track record in product innovation, branding, marketing and distribution through its portfolio of CPG brands. Harvest One owns and operates two subsidiaries; DreamWater^TM and LivRelief^TM. For more information, please visit www.harvestone.com.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the timing of the launch of the LivRelief Infused^TM Extra Strength Transdermal CBD Cream at the OCS, future increased revenues and sustainable success of the Company, and future expansion plans, initiatives and strategies of the Company.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s AIF, and under the heading “Risks and Uncertainties” in the Company’s Management’s Discussion and Analysis dated November 29, 2021, for the three months ended September 30, 2021, filed under the Company’s profile on SEDAR at www.sedar.com.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

Investor Relations:
Jack Tasse
Chief Financial Officer
[email protected]
1-877-915-7934

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.